Free Trial
NASDAQ:VERV

Verve Therapeutics (VERV) Stock Price, News & Analysis

Verve Therapeutics logo
$10.91 -0.04 (-0.37%)
Closing price 04:00 PM Eastern
Extended Trading
$10.98 +0.06 (+0.60%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Verve Therapeutics Stock (NASDAQ:VERV)

Key Stats

Today's Range
$10.90
$10.99
50-Day Range
$4.16
$11.38
52-Week Range
$2.86
$11.41
Volume
4.91 million shs
Average Volume
2.51 million shs
Market Capitalization
$972.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.57
Consensus Rating
Hold

Company Overview

Verve Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

VERV MarketRank™: 

Verve Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 465th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Verve Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Verve Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Verve Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Verve Therapeutics are expected to decrease in the coming year, from ($2.49) to ($2.83) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Verve Therapeutics is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Verve Therapeutics is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Verve Therapeutics has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Verve Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    9.36% of the float of Verve Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Verve Therapeutics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Verve Therapeutics has recently decreased by 38.06%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Verve Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Verve Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.36% of the float of Verve Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Verve Therapeutics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Verve Therapeutics has recently decreased by 38.06%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Verve Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Verve Therapeutics this week, compared to 7 articles on an average week.
  • Search Interest

    Only 11 people have searched for VERV on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Verve Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.90% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Verve Therapeutics' insider trading history.
Receive VERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERV Stock News Headlines

Man holds red arrow up over word Forecast.
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (VERV)
Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.
Critical AI announcement set to ignite AI 2.0
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
VERV Verve Therapeutics, Inc. - Seeking Alpha
See More Headlines

VERV Stock Analysis - Frequently Asked Questions

Verve Therapeutics' stock was trading at $5.64 on January 1st, 2025. Since then, VERV stock has increased by 93.4% and is now trading at $10.91.

Verve Therapeutics, Inc. (NASDAQ:VERV) released its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.36. The company had revenue of $32.98 million for the quarter, compared to analysts' expectations of $7.13 million. Verve Therapeutics had a negative net margin of 303.64% and a negative trailing twelve-month return on equity of 35.81%.

Verve Therapeutics (VERV) raised $201 million in an IPO on Thursday, June 17th 2021. The company issued 11,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO.

Verve Therapeutics' top institutional investors include Harbor Capital Advisors Inc. (0.05%) and Farther Finance Advisors LLC. Insiders that own company stock include Krishna Yeshwant, Andrew D Ashe, Sekar Kathiresan, Joan Nickerson, Allison Dorval, Andrew Bellinger and 2017 Gp LLC Gv.
View institutional ownership trends
.

Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verve Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
5/14/2025
Today
7/18/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VERV
CIK
1840574
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

High Price Target
$24.00
Low Price Target
$11.00
Potential Upside/Downside
+33.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.11)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$198.71 million
Net Margins
-303.64%
Pretax Margin
-303.10%
Return on Equity
-35.81%
Return on Assets
-27.57%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.84
Quick Ratio
9.84

Sales & Book Value

Annual Sales
$32.33 million
Price / Sales
30.08
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.83 per share
Price / Book
1.87

Miscellaneous

Outstanding Shares
89,140,000
Free Float
71,404,000
Market Cap
$972.52 million
Optionable
Optionable
Beta
2.23
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:VERV) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners